Merck immunotherapy drug shows promise against lymphoma: study

Merck & Co Inc's drug that harnesses the immune system to fight cancer showed promise in Hodgkin lymphoma patients whose disease had progressed following prior therapies, according to data from a small, early stage trial being presented at a medical meeting. In the ongoing study of 29 patients, 66 percent had a meaningful response to the drug, Keytruda, after 24 weeks of treatment, including six patients who achieved complete remission.

http://ift.tt/1yB25V0